Mar 14, 2019 / 06:05PM GMT
Gena Wang - Barclays Bank PLC, Research Division - Research Analyst
Good afternoon, everyone. My name is Gena Wang, I'm a mid-cap biotech analyst at Barclays. It is my great pleasure to introduce our next speaker, Stuart Peltz, Chief Executive Officer of PTCT; and also with us, we also have Marcio Souza, Chief Operating Officer, with us for the Q&A discussion.
Stuart W. Peltz - PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director
Can you hear me? Great. Well, thank you -- thanks for the introduction and the invitation to be here. We're PTC Therapeutics, I'm Stuart Peltz. I will be talking about some forward-looking statements and I suggest that you look at our findings.
So I'll go through a little bit of 2018, I'll just put these up.
My goal here is to give us time to have questions and answers to things that you have, but I wanted to start out and just say, obviously 2018 was truly a transformational year for PTC. Our DMD franchise did quite well and was within guidance. We able to expand Translarna's availability by getting
PTC Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 14, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers